Sionna Therapeutics, Inc.
NASDAQSionna Therapeutics has suffered one of the sharpest single-week crashes in small-cap biotech this year, falling 91% to $4.50 after the PreciSION Phase IIa readout delivered results that clearly failed to meet expectations. The analyst response was swift and brutal. Wedbush's Laura Chico — who initiated coverage just three months ago with an Outperform and a $53 target — downgraded…
SION cost to borrow surges to 2.17%, up 267% in one week as short sellers face rising borrow costs ahead of earnings.
Snapshot as of 25 Sept 2026
Sionna Therapeutics has suffered one of the sharpest single-week crashes in small-cap biotech this year, falling 91% to $4.50 after the PreciSION Phase IIa readout delivered results that clearly failed to meet…
Sionna Therapeutics heads into its August 11 earnings event with short sellers pulling back even as the stock's Phase 2a catalyst approaches — a split that puts the lending market and the clinical story in an unusual…
Sionna Therapeutics faces earnings tomorrow with three signals pointing the same direction. Short sellers are building positions, options traders are piling into calls, and the borrow market is tightening — all at…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SION — free to start on ORTEX.
Sign up for free →Open SION on ORTEX